Careers  |  Sign In  |  Register

Effect of Anti-Angiogenesis/Immunotherapy Combo in Poor-Risk RCC


Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society of Clinical Oncology annual meeting. The observations shared suggested that a combination of atezolizumab and bevacizumab lead to better progression-free survival rates. The full study results were published earlier this year in the journal Lancet.

Learn more by clicking here.